Clinical trials: Allogeneic Stem-Cell Transplant
Transplant-Related Disorder
Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.
To assess the effectiveness of interventions including health monitoring and regular return follow-up reminders for patients with a high Composite Immune Risk Score.
- Trial name
- NCT06208137
- Testing
- Health monitoring and regular return follow-up reminders
- Where
- China
- Volunteers
- 456 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Sickle Cell Disease
Analysis of T-Cell Immune Reconstitution Following Allogeneic Hematopoietic BMT for Severe SCD
In this study, patient blood samples from NMA transplants will be provided by Pittsburgh, and samples from myeloablative transplants will be provided by Atlanta (comparative controls).
- Trial name
- NCT00228631
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Emory University
Poor Graft Function, Hematopoietic Stem Cell Transplantation Complications
Expanded Donor Stem Cells for Poor Graft Function After Stem Cell Transplantation in Children
Poor graft function (PGF) is a serious complication after allogeneic hematopoietic stem cell transplantation (HSCT) and may cause persistent low blood cell counts despite donor-cell engraftment.
- Trial name
- NCT07907172
- Testing
- Ex vivo HEB-001-expanded donor-derived CD34+ hematopoietic stem cells
- Volunteers
- 3 people
- Sponsor
- wang xiaodong
Hematopoietic and Lymphoid Cell Neoplasm, Hematopoietic Cell Transplantation Recipient
Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
This randomized pilot phase I trial studies the side effects of human lysozyme goat milk in treating patients with blood cancer undergoing a donor stem cell transplant.
- Trial name
- NCT03531281
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Etoposide
- Where
- United States
- Sponsor
- City of Hope Medical Center
Allogeneic Hematopoietic Cell Transplantation
Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation
Alemtuzumab is an antibody that reduces the strength of the immune system that is given in preparation for allogeneic hematopoietic cell transplant (HCT).
- Trial name
- NCT05501756
- Testing
- Alemtuzumab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Epidermolysis Bullosa
Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Reduced Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (AlloSCT) from family-related donors and unrelated cord blood (UCB) donors will be safe and well tolerated in selected patients with RDEB.
- Trial name
- RDEB (NCT00881556)
- Testing
- Palifermin, Fludarabine, Busulfan
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Columbia University
Depression, Anxiety
Caregiver Burden and Distress in Hematopoeitic Stem Cell Transplant
The purpose of this study is to examine the impact that serving as a caregiver for a patient undergoing hematopoietic stem cell transplant has on the caregiver.
- Conditions
- Depression, Anxiety, Fatigue, Distress
- Trial name
- NCT01084694
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Northside Hospital, Inc.
Pneumococcal Infections
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)
The purpose of this study is to 1) evaluate the safety and tolerability, and immunogenicity of blinded V114 and Prevnar 13™ within each vaccination group, and 2) evaluate the safety and tolerability, and immunogenicity of…
- Trial name
- NCT03565900
- Testing
- V114, Prevnar 13™, PNEUMOVAX™23
- Where
- 52 sites in United States, Australia and 8 more
- Volunteers
- 277 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Myelomonocytic Leukemia (CMML), Immune Reconstitution
The Kinetics Profiling of Immune Reconstitution and Clinical Outcomes
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic malignancy with poor prognosis. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative treatment.
- Trial name
- NCT07113730
- Testing
- immune reconstitution
- Volunteers
- 300 people
- Sponsor
- Peking University People's Hospital
Graft-versus-host Disease
Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)
This is a phase I-II clinical trial. Adult subjects with hematological malignancies undergoing allogeneic HSCT from an HLA matched sibling or ≥7 out of 8 allele level HLA matched unrelated donor are eligible for the study if they…
- Trial name
- NCT05289167
- Testing
- Cyclophosphamide, Abatacept, Bortezomib
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Northwell Health
Adenovirus Infection
Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A)
Patients enrolled on this study will have received a stem cell transplant. After a transplant, while the immune system grows back the patient is at risk for infection.
- Trial name
- NCT02276820
- Testing
- Viralym-A
- Where
- 2 sites in United States
- Sponsor
- AlloVir
Myelodysplastic Syndromes
Hematopoietic Cell Transplantation With Post-transplantation Cyclophosphamide in MDS
This study is conducted to evaluate the feasibility and efficacy of post-transplantation cyclophosphamide with myeloablative or reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplantation (HCT) in…
- Trial name
- NCT02969980
- Testing
- Cyclophosphamide
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Asan Medical Center
Stem Cell Transplant Complications, Respiratory Disease
Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation
Bronchiolitis Obliterative Syndrome (BOS) is the primary noninfectious pulmonary complication after hematopoietic stem cell transplantation (HSCT) and usually carries a poor prognosis.
- Conditions
- Stem Cell Transplant Complications, Respiratory Disease, Bronchiolitis Obliterans
- Trial name
- RESPPEDOBS (NCT04655508)
- Testing
- Seretide
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Allogeneic Hematopoietic Stem Cell Transplantation
Antigen Specific Adoptive T Cell Therapy for Adenovirus Infection After Hematopoietic Stem Cell Transplantation
The purpose of this study is to determine if it is possible to treat an infection with a cell-based immunotherapy (therapy that uses the patient's own immune system to treat the infection).
- Trial name
- NCT03378102
- Testing
- IFN-gamma-secreting HAdV antigen specific T cells
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mari Dallas
Cytomegalovirus Infection
Alternate Donor Study of Pre-Emptive Cellular Therapy
The purpose of this study is to evaluate the potential clinical benefit of pre-emptive cytomegalovirus (CMV)-specific adoptive cellular therapy following T cell depleted allogeneic hematopoietic stem cell transplantation (HSCT)…
- Trial name
- CMV-ACE/ASPECT (NCT01220895)
- Testing
- CMV-specific T-cells, single infusion following single positive CMV PCR result
- Where
- 9 sites in United Kingdom
- Volunteers
- 52 people
- Sponsor
- Cell Medica Ltd
Lymphoma
Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma
Primary Objectives: 1. To evaluate the role of autologous and allogenic stem cell transplantation with Campath-1H for patients with peripheral T-cell lymphoma (PTCL). 2.
- Trial name
- NCT00505921
- Testing
- Campath-1H, G-CSF, GM-CSF
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Primary Immunodeficiencies, Inborn Errors of Metabolism
Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases
The aim of the trial is to describe the safety and efficacy of intravenous (i.v.) Treosulfan compared to the conventional (myeloablative) dose of i.v.
- Conditions
- Primary Immunodeficiencies, Inborn Errors of Metabolism, Haemoglobinopathies, Bone Marrow Failure Syndromes
- Trial name
- NCT02349906
- Testing
- Treosulfan, Busilvex
- Where
- 21 sites in Czechia, Germany and 2 more
- Volunteers
- 106 people
- Sponsor
- medac GmbH
Severe Congenital Neutropenia, GATA2 Deficiency
Total Lymphoid Irradiation Pre-HSCT in Severe Congenital Neutropenia
Severe congenital neutropenia (SCN) is a group of primary immunodeficiencies caused by distinct gene mutations and characterized by neutrophil maturation impairment, which leads to neutropenia, predisposition to severe bacterial…
- Trial name
- NCT04844177
- Testing
- conditioning with TLI
- Where
- Russia
- Volunteers
- 10 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Respiratory Distress Syndrome, Adult, Bronchiolitis Obliterans
Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation
The purpose of this study is to determine the effects of etanercept, and define the toxicity, when administered to patients with acute non-infectious lung injury (idiopathic pneumonia syndrome, IPS) and with subacute pulmonary…
- Conditions
- Respiratory Distress Syndrome, Adult, Bronchiolitis Obliterans, Pneumonia
- Trial name
- NCT00029328
- Testing
- etanercept
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- FDA Office of Orphan Products Development
Allogeneic Transplantation (Non T-cell Depleted)
Phase I Clinical Trial to Assess Safety of UV Phototherapy for the Prevention of GVHD Post Allogeneic SCT
The primary goal of thos study is to assess safety of Ultraviolet (UV) Phototherapy for the Prevention of Graft versus Host Disease after allogeneic stem cell transplantation (Phase I - Clinical trial).
- Trial name
- NCT00524953
- Testing
- EUMATRON - EN 600 NT
- Where
- Israel
- Sponsor
- Hadassah Medical Organization